Intracameral Bevacizumab for Iris Rubeosis

Salvatore Grisanti; Sabine Biester; Swaantje Peters; Olcay Tatar; Focke Ziemssen; Karl Ulrich Bartz-Schmidt

doi:10.1016/j.ajo.2006.02.045

Intracameral Bevacizumab for Iris Rubeosis

Salvatore Grisanti^*, Sabine Biester, Swaantje Peters, Olcay Tatar, Focke Ziemssen, Karl Ulrich Bartz-Schmidt

^*Corresponding author for this work

University of Tubingen

168 Citations (Scopus)

Abstract

Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.

Original language	English
Journal	American Journal of Ophthalmology
Volume	142
Issue number	1
Pages (from-to)	158-160
Number of pages	3
ISSN	0002-9394
DOIs	https://doi.org/10.1016/j.ajo.2006.02.045
Publication status	Published - 01.07.2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajo.2006.02.045

Cite this

@article{38b0d5634679468a8a054a15d01a84d8,

title = "Intracameral Bevacizumab for Iris Rubeosis",

abstract = "Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.",

author = "Salvatore Grisanti and Sabine Biester and Swaantje Peters and Olcay Tatar and Focke Ziemssen and Bartz-Schmidt, {Karl Ulrich}",

year = "2006",

month = jul,

day = "1",

doi = "10.1016/j.ajo.2006.02.045",

language = "English",

volume = "142",

pages = "158--160",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

number = "1",

}

TY - JOUR

T1 - Intracameral Bevacizumab for Iris Rubeosis

AU - Grisanti, Salvatore

AU - Biester, Sabine

AU - Peters, Swaantje

AU - Tatar, Olcay

AU - Ziemssen, Focke

AU - Bartz-Schmidt, Karl Ulrich

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.

AB - Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=33745413422&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.02.045

DO - 10.1016/j.ajo.2006.02.045

M3 - Journal articles

C2 - 16815268

AN - SCOPUS:33745413422

SN - 0002-9394

VL - 142

SP - 158

EP - 160

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 1

ER -

Intracameral Bevacizumab for Iris Rubeosis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this